Survival, and time to an advanced disease state or progression, of untreated patients with moderately severe multiple sclerosis in a multicenter observational database: relevance for design of a clinical trial for high dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation
Authors:
- 1 April 2006
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 12 (2) , 174-179
Abstract
Despite prolonged survival, patients with multiple sclerosis (MS) experience considerable morbidity, which adversely impacts quality of life. To assess the risk-benefit of a clinical trial of high dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation for MS, we sought to determine the natural history of the disease in a comparison group of untreated patients. We identified 285 individuals with 2132 combined observation years (median: 5.6 years; 5th to 95th percentile: 1-21 years), with Expanded Disability Status Scale (EDSS) scores of 3.0-5.5 at baseline observation. Disease-related mortality was zero at five years, 5.4% at 10 years, and 22% at 15 years (40 patients contributing to the data point; 95% confidence interval: 4-32%). Risk for progression to advanced disability, defined as an EDSS score of 8, was very low for the subgroup with a baseline EDSS score of 3-3.5; however, for those with a baseline EDSS score of 4-5.5, 3% had advanced disability after two years, 5% after three years, 6% after four years, 12% after five years, and 40% after 10 years. The estimated probability of disease progression, defined as an increase in EDSS score by ≥ 1.0 sustained for at least 180 days, was 5% after one year, 14% after two years, 22% after three years, 38% after five years, 57% after 10 years, and-80% after 20 years of observation. The relevance of these features to the design of the clinical trial is discussed.Keywords
This publication has 33 references indexed in Scilit:
- Autologous hemopoietic stem cell transplantation in the treatment of multiple sclerosis: rationale and clinical experienceJournal of the Neurological Sciences, 2004
- Multiple sclerosisBest Practice & Research Clinical Haematology, 2004
- Immune events following immunoablative therapy for the treatment of multiple sclerosis (MS)Transplantation and Cellular Therapy, 2004
- Suppressing immunity in advancing MSNeurology, 2004
- Stem cell transplantation for multiple sclerosis: What is the evidence?Blood Reviews, 2003
- High-Dose Immunosuppression and Autologous Hematopoietic Stem Cell Rescue for Severe Multiple SclerosisJournal of Hematotherapy & Stem Cell Research, 2003
- Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation–based conditioning regimen to prevent disease progression in patients with high disability scoresBlood, 2003
- High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosisBlood, 2003
- Hematopoietic stem cell transplantation for multiple sclerosis: current status and future challengesCurrent Opinion in Neurology, 2003
- Hematopoietic stem cell transplantation for multiple sclerosisJournal of Neurology, 2002